SELECT Trial

Study / Research

A significant study, sponsored by Nova Nordisk, that showed a 20% reduction in severe cardiovascular events in overweight individuals (without Type 2 diabetes) on Semaglutide, independent of weight loss.

Mentioned in 2 videos